ARTICLE | Financial News
With $69M D round, Adagene looks to Phase II for solid, blood cancers
January 8, 2020 9:35 PM UTC
Updated on Jan 9, 2020 at 8:33 PM UTC
Adagene plans to use a $69 million series D round take its solid tumor and non-Hodgkin lymphoma candidate into the first Phase II trial for an antibody developed with the company's computational design platform.
The series D round includes $50 million from lead investor General Atlantic and brings the total venture funding raised by Suzhou-based Adagene Inc. to over $150 million since its founding in 2012. Other investors in the round were not disclosed...